Peritoneal tuberculosis after imatinib therapy.
Senn
Laurence
L
Kovacsovics
Tibor
T
Tarr
Philip E
PE
Meylan
Pascal
P
D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000995:Antitubercular Agents / Q000627:therapeutic use; D001549:Benzamides; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy; D008231:Lymphopenia / Q000139:chemically induced; D008297:Male; D009894:Opportunistic Infections / Q000139:chemically induced / Q000150:complications* / Q000188:drug therapy; D010538:Peritonitis / Q000382:microbiology; D014395:Peritonitis, Tuberculous / Q000139:chemically induced / Q000150:complications* / Q000188:drug therapy; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects*; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects*
D000970:Antineoplastic Agents; D000995:Antitubercular Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate